| Jennifer Maxwell Mcwilliams, PTA | |
|
411 Lenover Rd, Atglen, PA 19310-1763 | |
| (610) 593-4824 | |
| Not Available |
| Full Name | Jennifer Maxwell Mcwilliams |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 411 Lenover Rd, Atglen, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588193635 | NPI | - | NPPES |
| TE1002922 | Other | PA | PTA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | TE1002922 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Maxwell Mcwilliams, PTA 411 Lenover Rd, Atglen, PA 19310-1763 Ph: () - | Jennifer Maxwell Mcwilliams, PTA 411 Lenover Rd, Atglen, PA 19310-1763 Ph: (610) 593-4824 |
News Archive
The Food and Drug Administration has cleared for marketing a new laboratory blood test that will help doctors screen newborn infants for a variety of inherited diseases.
Developing the advanced and powerful detection techniques to characterize as many endocrine disruptors as possible with ultra-sensitivity in the environment is still challenging, however highly demanded.
Pericytes are the primary locus of matrix-mellaproteinase-9-dependent (MMP-9) capillary damage and blood leakage during ischemia, according to preclinical findings reported by Medical University of South Carolina investigators in an article published online on November 14, 2016 by The Journal of Neuroscience.
CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm and Medifacts International in February of this year, has recently completed the first ever regulatory mandated Thorough QT (TQT) study conducted in the Asia Pacific Rim and the first TQT study for a Japanese new drug application (NDA).
For the first six months, IT and medical technology company Sectra reported a 15.8% increase in net sales to SEK 453.6 million (391.7). Operating profit totaled SEK 7.6 million (16.5), corresponding to an operating margin of 1.7% (4.2). Profit after net financial items was SEK 2.4 million (4.4).
› Verified 2 days ago